Patents Assigned to Acepodia Biotechnologies Ltd.
  • A NOVEL CD16+ NATURAL KILLER CELL AND A METHOD OF CULTURING CD16+ NATURAL KILLER CELL
    Publication number: 20230036481
    Abstract: The present invention provides a human CD16+ natural killer cell line and a CAR-expressing human CD16+ natural killer cell line. These human CD16+ natural killer cell line and a CAR-expressing human CD16+ natural killer cell line does not include synthetic, genetically modified or purposely deliberately delivered polynucleotide encoding the CD16 receptor and are non-tumorigenic cell lines. Therefore, this human CD16+ natural killer cell line and a CAR-expressing human CD16+ natural killer cell line might provide considerable long-term safety for disease treatment.
    Type: Application
    Filed: January 15, 2021
    Publication date: February 2, 2023
    Applicant: Acepodia Biotechnologies Ltd.
    Inventors: SAI-WEN TANG, ZIH-FEI CHENG, CHIA-YUN LEE, HAO-KANG LI, HSIU-PING YANG, CHING-WEN HSIAO, SEN HEN YANG, TAI-SHENG WU, YAN-LIANG LIN, YAN-DA LAI, SHIH-CHIA HSIAO
  • A NOVEL CD16+ NATURAL KILLER CELL AND A METHOD OF CULTURING CD16+ NATURAL KILLER CELL
    Publication number: 20220073878
    Abstract: The present invention provides a human CD16+ natural killer cell line. This human CD16+ natural killer cell line does not include synthetic, genetically modified or deliberately delivered polynucleotide encoding the CD16 receptor and is a non-tumorigenic cell line. Therefore, this human CD16+ natural killer cell line might provide considerable long-term safety for disease treatment.
    Type: Application
    Filed: January 16, 2020
    Publication date: March 10, 2022
    Applicant: Acepodia Biotechnologies Ltd.
    Inventors: Zih-Fei Cheng, Chia-Yun Lee, Hao-Kang Li, Yan-Liang Lin, Ching-Wen Hsiao, Yan-Da Lai, Yu-Pei Cheng, Hsiu-Ping Yang, Shih-Chia Hsiao